IN THE CLAIMS:

Amend Claims 1 and 14 as follows:

Claim 1 (amended)

A2

A pharmaceutical composition for the treatment of a malignant disease or condition in a mammal, the composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula

$$R_1$$
 R_1
 R_1
 R_1
 R_1
 R_2
 R_3
 R_1
 R_3
 R_4
 R_4
 R_5
 R_6
 R_7
 R_8
 R_1
 R_1
 R_1
 R_2
 R_3
 R_4
 R_5
 R_6
 R_7
 R_8

(Prop. B)

where X is S or O;

R₁ is, independently, H or lower alkyl of 1 to 6 carbons;

R₂ and R₃ are, independently, H, lower alkyl of 1 to 6 carbons, F, Cl, Br, I, alkoxy of 1 to 6 carbons, or fluoroalkoxy of 1 to 6 carbons;

m is an integer 0 to 3;

o is an integer 0 to 4;

n is 0-5;

Y is phenyl, naphthyl, or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl pyridazinyl, pyrimidinyl, pyrazinyl; oxazolyl, thiazolyl, or imidazolyl; and

B is COOH, a pharmaceutically acceptable salt thereof, CONR₆R₇ or COOR₈ where R_6 and R_7 , independently, are hydrogen or an alkyl group of 1 to 6 carbons and R_8 is alkyl of 1 to 6 carbons,

said composition being adapted to be used in combination with another chemotherapeutic agent effective for the treatment of the malignant disease or



condition of the mammal where the composition in combination with the other chemotherapeutic agent shows synergistic effect.

Claim 14 (amended)

£3

A method of treating a malignant disease or condition in a mammal in need of such treatment, the method comprising the steps of:

administering to said mammal a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula

$$R_1$$
 R_1
 $Y(R_2)_0$
 $CH_2)_n$
 R_1
 R_1
 R_1
 R_2
 R_3
 R_4

where X is S or O;

 \mathbf{R}_1 is, independently, H or lower alkyl of 1 to 6 carbons;

R₂ and R₃ are, independently, H, lower alkyl of 1 to 6 carbons, F, Cl, Br, I, alkoxy of 1 to 6 carbons, or fluoroalkoxy of 1 to 6 carbons;

m is an integer 0 to 3;

o is an integer 0 to 4;

n is 0-5;

Y is phenyl, naphthyl, or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl; oxazolyl, thiazolyl, or imidazolyl;

B is COOH, a pharmaceutically acceptable salt thereof, CONR₆R₇ or COOR₈ where R_6 and R_7 , independently, are hydrogen or an alkyl group of 1 to 6 carbons and R_8 is alkyl of 1 to 6 carbons, and